Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 615

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 2
Chunk 615
---

     (2,829,723)

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Proceeds from note payable-related party 
     250,000  
     — 
  
    Repayment of note payable-related party 
     (59,730) 
     (685,473)
  
    Proceeds from convertible notes payable 
     790,000  
     3,935,000 
  
    Proceeds from issuance of common stock, warrants and pre-funded warrants, net of placement agent fees of $504,770 
     3,992,675  
     — 
  
    Payment of other issuance costs for issuance of common stock and equity-classified warrants 
     (235,707) 
     — 
  
    Payment for issuance costs related to liability-classified warrants 
     (28,477) 
     — 
  
    Proceeds from exercise of pre-funded warrants 
     729  
     (345,000)
  
    Payment for convertible notes finance costs 
     (107,491) 
     (334,444)
  
    Payment of convertible note payable 
     (846,806) 
     — 
  
    Net cash provided by financing activities 
     3,755,193  
     2,570,083 

    Net change in cash and cash equivalents 
     (656,272) 
     (5,840,787)
  
    Cash and cash equivalents, beginning of period 
     2,576,416  
     8,417,203 
  
    Cash and cash equivalents, end of period 
    $1,920,144  
    $2,576,416 

    Cash paid for: 

    Interest 
    $86,589  
    $164,807 
  
    Income taxes 
    $—  
    $— 

    Supplemental non-cash financing activities: 

    Common stock issued for settlement of debt 
    $1,947,294  
    $2,697,849 
  
    Warrants issued for financing fees, net of issuance fees of $0 and $8,727, respectively 
    $—  
    $90,816 
  
    Initial recognition of right of use asset and liability 
    $—  
    $365,556 

The
accompanying notes are an integral part of